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ABSTRACT
Empirical antibiotic therapy of community-acquired pneumonia (CAP) has been complicated by the world-
wide emergence of penicillin resistance among Streptococcus pneumoniae. The impact of this resistance on the
outcome of patients hospitalized for CAP, empirically treated with betalactams, has not been evaluated in a
randomized study. We conducted a prospective, randomized trial to assess the efficacy of amoxicillin-clavu-
lanate (2 g/200 mg/8 hr) and ceftriaxone (1 g/24 hr) in a cohort of patients hospitalized for moderate-to-se-
vere CAP. Three-hundred seventy-eight patients were randomized to receive amoxicillin-clavulanate (184 pa-
tients) or ceftriaxone (194 patients). Efficacy was assessed on Day 2, after completion of therapy and at long
term follow-up. There were no significant differences in outcomes between treatment groups, both in inten-
tion-to-treat and per-protocol analysis. Overall mortality was 10.3% for amoxicillin-clavulanate and 8.8% for
ceftriaxone (NS). There were 116 evaluable patients with proven pneumococcal pneumonia. Rates of high-
level penicillin resistance (MIC of penicillin$2 l g/mL) were similar in the two groups (8.2 and 10.2%). Clin-
ical efficacy at the end of therapy was 90.6% for amoxicillin-clavulanate and 88.9% for ceftriaxone (95% C.I.
of the difference: 2 9.3 to 1 12.7%). No differences in outcomes were attributable to differences in penicillin
susceptibility of pneumococcal strains. Sequential i.v./oral amoxicillin-clavulanate and parenteral ceftriaxone
were equally safe and effective for the empirical treatment of acute bacterial pneumonia, including penicillin
and cephalosporin-resistant pneumococcal pneumonia. The use of appropriate betalactams in patients with
penumococcal pneumonia and in the overall CAP population, is reliable at the current level of resistance.
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INTRODUCTION
EMPIRICAL ANTIBIOTIC THERAPY of community-acquiredpneumonia (CAP) is a controversial medical topic to-
day.3,14 This is largely due to the worldwide emergence of an-
tibiotic resistance among Streptococcus pneumoniae, which 
remains the most frequent cause of CAP requiring hospitaliza-
tion.2,7,25 One of the main issues regarding CAP therapy is
whether or not betalactams can be used successfully against be-
talactam-resistant pneumococci. In a previous, nonrandomized
study, we have shown that intravenous high-dose penicillin and
some expanded-spectrum cephalosporins were effective for the
treatment of pneumococcal pneumonia caused by strains with
minimal inhibitory concentrations (MICs) up to 2 mg/mL.29
However, the MICs of penicillins and cephalosporins above
which therapeutic failures would be expected are not known.18
In addition, the impact of penicillin resistance on the outcome
of a large cohort of patients with CAP receiving empirical be-
talactam therapy has not been evaluated prospectively. Most
authorities do recommend third-generation cephalosporins or
betalactam-betalactamase inhibitors as the first line therapy for
hospitalized CAP, but suggest the use of alternative drugs such
as vancomycin or fluoroquinolones for strains resistant to peni-
cillin (MIC$ 2 mg/mL), or as empirical therapy in critically
ill patients; however these suggestions are based on ‘in vitro’
data, and firm recommendations must await additional con-
trolled studies.1,3,16,32
To address these issues in an area with high prevalence of
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antibiotic-resistant pneumococci, we performed a randomized
trial, comparing two commonly used betalactam agents in the
treatment of moderate-to-severe CAP: amoxicillin-clavulanate
and ceftriaxone. MICs of both antibiotics against resistant pneu-
mococci are usually lower than that of penicillin G and their
broad-spectrum makes them safe enough for empirical therapy
of CAP of presumed bacterial etiology.23,33
PATIENTS AND METHODS
Study design
The design was conducted at Bellvitge Hospital, a 1000-bed
University hospital in Barcelona, Spain, which serves an area
of 1,100,000 inhabitants. It was comparative, prospective, ran-
domized, and assessor-blinded in early assessments. All patients
included gave informed consent to enter, and the study was ap-
proved by the Ethical Committee at our institution.
Patient eligibility
All nonimmunosuppressed adult patients with moderate-to-
severe CAP who were admitted to the hospital from February
1995 through May 1997 were considered for study inclusion.
Patients were excluded if they met one or more of the follow-
ing criteria: unwillingness to enter the study; age#16 years;
hypersensitivity to b-lactam antibiotics; pregnancy or breast-
feeding; immunosuppression (AIDS, end-stage neoplasia, cy-
totoxic therapy, absolute neutropenia, or transplantation); shock
unresponsive to therapy; concomitant endocarditis or meningi-
tis; high clinical suspicion of Legionella, atypical, viral or as-
piration pneumonia; previous antibiotic therapy for more than
24 h; and previous hospitalization within the past 14 days.
Randomization
Eligible patients were randomized by the infectious disease
consultant, who opened sealed, sequentially numbered en-
velopes. Random blocks of 25 allocations equally divided be-
tween regimens were used. Patients were assigned to receive
either i.v. amoxicillin-clavulanate (2 g/200 mg every 8 hr) or
i.v. ceftriaxone (1 g every 24 hr) for at least 72 hr. After a sig-
nificant clinical improvement was achieved, sequential oral
amoxicillin-clavulanate (1 g/125 mg every 8 hr) or i.m. ceftri-
axone (1 g every 24 hr) were initiated. The addition of intra-
venous erythromycin at randomization was allowed if indicated
by the attending physician. No other antibiotic therapy was per-
mitted during the study period. All medication was provided by
the hospital pharmacy.
Definitions
CAP was defined as an acute respiratory illness associated
with one or more of the following: fever or hypothermia, cough,
sputum production, pleuritic chest pain, dyspnea, altered breath
sounds on auscultation; plus the presence of a new infiltrate on
a chest radiograph. CAP was considered moderate-to-severe
when one or more of the following criteria was present: age
$70 years; PaO2 , 60 mmHg or PaO2/FiO2 , 300; multilobar
radiological involvement; hypotension or shock; and underly-
ing disease such as alcoholism, chronic obstructive pulmonary
disease (COPD), congestive heart failure, renal failure, splenec-
tomy and diabetes mellitus. The simplified acute physiology
score (SAPS) was applied as described elsewhere.19 To strat-
ify patients in risk classes we used the validated prediction rule
calculated according to the Pneumonia Severity Index (PSI)
scores, developed by the Pneumonia Outcomes Research Team
as described elsewhere.11 Overall mortality was defined as
death by any cause within 30 days of hospitalization.
Etiological diagnosis of CAP was considered definitive when
there was: isolation of a respiratory pathogen from a normally
sterile specimen; isolation of L. pneumophila or Mycobacterium
tuberculosis from sputum; detection of pneumococcal antigens
by latex agglutination or pneumococcal DNA by polymerase
chain reaction (PCR) in pleural fluid or transthoracic needle as-
piration (TNA) specimens; detection of L. pneumophila
serogroup 1 antigen in urine; four-fold increase in the antibody
titre or seroconversion for Mycoplasma pneumoniae, Chlamy-
dia psittaci, Chlamydia pneumoniae, Coxiella burnetii, L. pneu-
mophila, respiratory syncytial virus, influenza A virus and
parainfluenza 3 virus. Etiological diagnosis was considered pre-
sumptive when a predominant microorganism that correlated
with a predominant morphotype in the Gram stain was isolated
from sputum samples of good quality [presence of .25 poly-
morphonuclear leukocytes and ,10 squamous cells per low-
magnification field (310]. Presumptive aspiration pneumonia
(anaerobic infection) was diagnosed on a clinical and radio-
logical basis, in patients with specific risk factors. The re-
maining cases were considered as pneumonia of unknown eti-
ology.
Clinical and bacteriological evaluation
At the initial visit and before starting antibiotic therapy, each
patient underwent a complete history and physical examination.
Chest radiographs, arterial blood gas determinations, and basic
chemistry and hematology tests were performed. Two sets of
blood cultures were drawn and a sputum sample was processed
for Gram stain and culture if available. Invasive procedures such
as bronchoscopy or TNA were performed if indicated by the
attending physician.
Follow-up visits were performed daily during hospital stay.
Chest radiographs, hematology and chemistry tests, and re-
peated sputum cultures, if obtainable, were performed on Day
2, at the end of study and at the long-term follow-up visit, ap-
proximately 1 month after discharge. Blood cultures were re-
peated at 48 hr if initially positive, and when clinically indi-
cated.
Microbiological studies
Investigation of pathogens in blood, normally sterile fluids,
sputum and TNA samples and serological studies were per-
formed by standard microbiological procedures. Latex aggluti-
nation and PCR detection of S. pneumoniae was performed in
TNA samples as described elsewhere.13 Detection of L. pneu-
mophila serogroup I antigen in urine was performed by an im-
munoenzymatic commercial method (Legionella Urinary Anti-
gen, Binax, Portland, ME).
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Susceptibility tests in H. influenzae strains were performed
by a microdilution method with Haemophilus test medium, as
described in NCCLS standards.27 Detection of betalactamase
production was performed by using a commercial chromogenic
cephalosporin test (Nitrocefin; Cefinase; Becton Dickinson Mi-
crobiology Systems, Cockeysville, MD).
Susceptibility tests of S. pneumoniae strains were performed
by a microdilution method with Mueller–Hinton broth (Ca11
and Mg11 cation-adjusted) supplemented with 5% lysed horse
blood, as described in NCCLS standards.27 The antibiotics
tested were: penicillin, amoxicillin-clavulanate, ceftriaxone,
erythromycin, clindamycin, tetracycline, chloramphenicol, and
trimethoprim-sulfamethoxazole. MIC was defined as the low-
est concentration of antimicrobial that prevented visible growth
after an overnight incubation of plates at 35°C. Resistance to
antimicrobial agents was defined according to the NCCLS cri-
teria.26 Serotyping of pneumococcal strains was performed at
the Spanish Pneumococcal Reference Laboratory (Majada-
honda, Madrid) by detecting the quellung reaction with use of
46 antisera provided by the Staten Seruminstitut (Copen-
haguen).
Assessment of efficacy
Clinical efficacy was assessed three times during follow-up.
The first evaluation, “early assessment,” took place on Day 2.
Two experienced clinical investigators (F.M. and F.G., in most
cases), who were blind to the treatment regimen, classified the
response as: (1) improvement, when the acute symptoms had
clearly regressed; (2) failure, in any of the following circum-
stances: no apparent clinical response to therapy, septic metas-
tases, previously unrecognised shock or hemodynamic failure,
worsening of respiratory failure, radiological progression, or se-
vere adverse events; and (3) indeterminate, when improvement
was insufficient. In these cases, a new clinical evaluation was
performed 24 hr later and the case was definitively classified
as failure or improvement.
The second evaluation, “end of therapy assessment,” was
performed 24–48 hr after completion of therapy. Cases were
classified as: (1) cure, when clinical findings of pneumonia had
disappeared and there was radiological improvement; (2) fail-
ure, under the following circumstances: lack of improvement,
superinfection, inability to complete treatment due to adverse
events, or death by any cause.
The third evaluation, “final assessment,” was performed at
the long-term follow-up visit. Cases were classified as: (1) cure,
when there was clinical and radiological resolution; (2) failure,
when there was persistence or recrudescence of symptoms, or
any case previously classified as failure; and (3) unevaluable
per protocol analysis, when a noninfectious cause of pulmonary
infiltrates was documented, or if patients did not attend the fol-
low-up visit. Assessment of health status of all patients not at-
tending the visit was attempted by telephone contact.
Only culture-positive pneumonias were considered for bac-
teriological evaluation, which was performed three times dur-
ing follow-up: at 48 hr of therapy, after completion of treat-
ment, and at the long-term follow-up visit. Response was
classified as satisfactory if there was eradication of the mi-
croorganism or if respiratory samples could not be obtained due
to improvement; unsatisfactory, if the previously identified
pathogen was still isolated, or when superinfection requiring
additional antimicrobial therapy occurred; and indeterminate,
when the evaluation could not be performed for any reason.
Statistical analysis
The trial was designed under the hypothesis that clinical cure
rate would be equivalent in the treatment groups. The sample
size was determined in order to detect a 15% difference in the
clinical cure rate for pneumococcal pneumonia, if the expected
clinical cure rate using parenteral ceftriaxone in patients with
moderate-to-severe pneumococcal pneumonia was 80%. With
a power of 80% [type II error (b)5 0.20] and using a two-
sided 95% confidence interval [type I error (a) 5 0.05], 75
evaluable patients per treatment group were required. Consid-
ering that S. pneumoniae would cause around 50% of moder-
ate-to-severe bacterial CAP, and allowing for 15% unevalua-
bility, a total of 345 patients was needed.
Comparisons between groups were performed by a x2 test
with continuity correction or an independent sample t-test, when
appropriate. Significance was defined at a P value, 0.05 us-
ing a two-sided test.
For assessment of clinical efficacy, two analyses were per-
formed: an intention-to-treat analysis, including all randomized
patients, and a per protocol analysis of all evaluable patients.
Special emphasis was placed on the assessment of response in
proven pneumococcal pneumonia, with subanalysis of peni-
cillin-resistant cases. A two-sided 95% confidence interval was
calculated for the difference in success rates between the two
treatment groups.
RESULTS
Trial profile
Of the 543 patients who were considered for inclusion dur-
ing the study period, 378 were finally randomized to receive
amoxicillin-clavulanate (184 patients) or ceftriaxone (194 pa-
tients) and analyzed by intention-to-treat. After excluding 55
additional unevaluable patients, the remaining 323 were con-
sidered evaluable and analyzed per protocol. Figure 1 illustrates
the trial profile. We kept a book log with the diagnosis and out-
come of all nonrandomized patients.
Characteristics of patients
Table 1 shows the baseline characteristics of the 378 ran-
domized patients. There were no differences between treatment
groups, including the distribution of most significant underly-
ing diseases, such as cancer, COPD, chronic heart disease, and
diabetes mellitus. Baseline characteristics of the 323 evaluable
patients and the 115 patients with proven pneumococcal pneu-
monia were also similar.
Etiology
Table 2 shows the distribution of causative organisms of the
323 evaluable cases, in both treatment groups. In 83 (52.9%)
pneumonias of the amoxicillin-clavulanate group and 86
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(51.8%) of the ceftriaxone group no pathogens were identified.
Overall, S. pneumoniae was the most frequently identified
causative agent, accounting for 71.6 and 78.7% of pneumonias
with a proven etiology respectively, and 34.9% of the total ill-
nesses included in the study.
Antibiotic therapy
Mean duration of i.v. therapy was 5.4 days for the amoxi-
cillin-clavulanate group and 5.3 days for the ceftriaxone group
(p 5 0.63). Complete duration of antibiotic therapy was 10.9
days and 10.1 days, respectively (p 5 0.18). Seventeen patients
(9.2%) in the amoxicillin-clavulanate group and 25 patients
(12.9%) in the ceftriaxone group initially received combination
erythromycin therapy. Seven patients with proven pneumococ-
cal pneumonia (2 and 5, respectively) received combination
therapy with erythromycin. In five of them the diagnosis was
performed by isolation of S. pneumoniae. Four of these strains
were fully sensitive to penicillin (MIC , 0.03 mg/mL) and the
remaining had an MIC of 2 mg/mL.
Intention-to-treat analysis
Patients were hospitalized for a mean of 10.7 days in the
amoxicillin-clavulanate group and 11.3 days in the ceftriaxone
group. Fourteen patients in each group required intensive care
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TABLE 1. BASELINE CHARACTERISTICS OF ALL RANDOMIZED PATIENTS
Amoxicillin-clavulanate Ceftriaxone
Characteristic No. (%) No. (%)
Patients 184.0 194.0
Age, y (mean) 66.0 67.0
Sex (male/female) 123/61 144/50
Underlying disease 130 (70.7) 147 (75.8)
Previous antibiotic therapy 35 (19.0) 35 (18.0)
Influenza vaccine 75 (40.8) 96 (49.5)
Pneumococcal vaccine 10 (5.4) 5 (2.6)
Impaired consciousness 19 (10.3) 26 (13.4)
Multilobar infiltrate 52 (28.3) 62 (32.0)
Shock at onset 7 (3.8) 5 (2.5)
PSI classes (IV-V) 110 (59.8) 113 (58.2)
SAPS (mean) 9.4 9.4
Axillary temperature (mean) ºC 38.2 38.2
Respiratory rate per min (mean) 29.0 30.0
PO2/FiO2 (mean) 274.0 270.0
Empyema 10 (5.4)0 11 (5.7)
Bacteremia 20 (10.9) 26 (13.4)
No differences were statistically significant. SAPS, Simplified acute physiol-
ogy score; and PSI, pneumonia severity index.
FIG. 1. Trial profile.
unit (ICU) admission and most of them underwent mechanical
ventilation (10 and 10). In-hospital complications were ob-
served in 51 (27.7%) and 54 (27.8%) patients, respectively, the
most frequent being congestive heart failure (10 and 9), and
pleural empyema (10 and 11).
As shown in Table 3, there were no significant differences
in clinical efficacy between the two treatment groups in any of
the three assessments. In the final assessment, the success rates
were 73.9 and 74.2%, respectively. Overall mortality was sim-
ilar among patients receiving amoxicillin-clavulanate (10.3%)
and those receiving ceftriaxone (8.8%).
Both drugs were well tolerated, and most adverse events were
mild; only two patients stopped treatment due to adverse events.
Forty-one patients (22.2%) in the amoxicillin-clavulanate group
and 34 patients (17.5%) in the ceftriaxone group presented drug-
related adverse events, the most frequent being phlebitis (30
and 25) and gastrointestinal discomfort (9 and 2).
Patients excluded after randomization
Fifty-five patients were excluded from the per protocol
analysis, 27 in the amoxicillin-clavulanate group and 28 in the
ceftriaxone group. Most had noninfectious pulmonary infiltrates
or atypical or Legionella pneumonia. Table 4 shows causes of
exclusion and mortality of these patients.
Per protocol analysis
One hundred and fifty-seven patients in the amoxicillin-
clavulanate group and 166 in the ceftriaxone group were evalu-
able per protocol. Nine and 11 patients, respectively, were not
assessable at the long-term follow-up visit (3 and 5 patients in
good health refused to attend the visit, 3 and 4 patients died for
cause unrelated to infection, 2 and 2 patients could not be lo-
cated, and AIDS was diagnosed in one patient in the amoxi-
cillin-clavulanate group). As shown in Table 3, there were no
differences in clinical efficacy and mortality between groups.
Overall, 38 patients had an unsatisfactory response throughout
the study. Criteria for considering these patients as failures are
summarized in Table 5. Bacteriological efficacy, assessed in
137 cases, was 92.4 and 95.8%, respectively.
Antibiotic susceptibilities and pneumoccal
serogroups/types
Overall, 88.9% of the isolated pathogens were susceptible to
amoxicillin-clavulanate, and 89.6% were susceptible to ceftri-
axone. Susceptibilities of 105 S. pneumoniae strains are shown
in Table 6. There were four (3.8%) strains of pneumococci with
penicillin MICs of 4 mg/mL, and 11 (10.5%) strains showed
multiple-resistance. MICs of amoxicillin (and amoxicillin-
clavulanate) and ceftriaxone were similar, ranging from 0.015
to 2 mg/mL. Five strains showed a MIC of 2 mg/mL for amox-
icillin (2 in the amoxicillin-clavulanate group and 3 in the cef-
triaxone group) and four strains had a MIC of 2 mg/mL for cef-
triaxone (2 and 2). Twenty-two different serogroups/types
(SGT) were found among the 105 pneumococci isolates. Eight
SGT accounted 79.8% of strains (83/105). The more frequent
SGT were: 3 (34.3%); 8 (11.4%); 4 (7.6%); 19 (6.7%); 14
(5.7%); 9 (5.7%); 23 (4.8%), and 6 (2.9%).
Among the 28 H. influenzae isolates, b-lactamase produc-
tion was detected in 17.9% of strains and no strain was resis-
tant to the study drugs.
Pneumococcal pneumonia
There were 116 evaluate patients with proved pneumococ-
cal pneumonia; 53 received amoxicillin-clavulanate and 63 cef-
triaxone. Rates of high-level penicillin resistance were similar
(8.2 and 10.2%). Table 7 shows treatment and outcomes of these
patients. There were seven early clinical failures (four amoxi-
cillin-clavulanate and three ceftriaxone), none of them pre-
sumably related to antibiotic resistance. Clinical efficacy at the
end of therapy was 90.6 and 88.9%, respectively (95% C.I. of
the difference, 29.3% to 112.7%). Mortality at 30 days was
9.4 and 11.1%, respectively. A satisfactory outcome at the end
of therapy was observed in 76 (90.5%) of patients with peni-
cillin-susceptible strains and in 18 (85.7%) of patients with
penicillin-resistant strains (p 5 0.81). No relapses were ob-
served at long-term follow-up. A detailed analysis of patients
with pneumococcal pneumonia who were classified as failures
at any assessment is provided in Table 8.
Among patients receiving amoxicillin-clavulanate, a satis-
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TABLE 2. DISTRIBUTION OF CAUSATIVE AGENTS IN 323 EVALUABLE
PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA ACCORDING
TO TREATMENT GROUPS
Causative agentsa Amoxicillin-clavulanate Ceftriaxone
Patients 157 166
Streptococcus pneumoniae 53 63
Haemophilus influenzae 15 13
Moraxella catarrhalis 3 3
Enterobacteriaceae 1 3
Others 5 1
Atypical agentsb 4 5
No pathogen identified 83 (52.9%) 86 (51.8%)
aThe sum is more than 323 because fifteen patients had mixed infections
(7 in amoxicillin-clavulanate group and 8 in ceftriaxone group).
bAll of these patients had mixed infections.
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factory outcome at the end of therapy was observed in 39
(88.6%) of amoxicillin-susceptible strains and in 5 (100%) of
amoxicillin-resistant strains (p 5 0.98). Among patients re-
ceiving ceftriaxone, a satisfactory outcome at the end of ther-
apy was observed in 44 (91.7%) of cephalosporin-susceptible
strains and in 6 (75.0%) of cephalosporin-resistant strains (p 5
0.42).
DISCUSSION
The worldwide emergence of penicillin resistance among
Streptococcus pneumoniae has complicated the treatment of
pneumococcal pneumonia and, consequently, the empirical
therapy of the entire group of patients with suspected bacterial
CAP. To date, the clinical relevance of “in vitro” resistance to
betalactams in these infections is unclear and there is no uni-
versally accepted “gold standard” for the treatment of resistant
pneumococcal pneumonia (16,18,32). In this randomized trial
evaluating a large population of patients with CAP who ful-
filled previously defined hospitalization criteria, amoxicillin-
clavulanate and cefriaxone were found to be equally safe and
effective. Rates of failure and mortality were in the low range
of those reported for moderate-to-severe CAP, both in the to-
tal group of patients and in the subset of patients with proven
pneumococcal pneumonia.11,12,38 We also found no significant
difference in outcomes attributable to penicillin susceptibility
of pneumococcal strains and no differences attributable to treat-
ment regimens in penicillin and cephalosporin-resistant pneu-
mococcal pneumonia. Nevertheless, when interpreting our find-
ings it should be kept in mind the small number of highly
resistant strains isolated in our trial.
Our data are useful for assessing the efficacy of betalactam
therapy for CAP of suspected bacterial etiology, in an area of
high prevalence of penicillin-resistant pneumococci, especially
taking into account that only a low proportion of patients re-
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TABLE 4. PATIENTS EXCLUDED AFTER RANDOMIZATION:
CAUSES AND OUTCOME
Causes of exclusion Amoxicillin-clavulanate Ceftriaxone
No. of patients 27 28
Misrandomization 10 8
No pneumonia 7 5
No severity criteria 3 —
AIDS — 2
Unresponsive shock — 1
Protocol violation 3 7
Atypical agents 11 11
Legionella 4 3
Atypical 6 5
Others 1 3
Aspiration pneumonia 3 2
Overall mortality 4 1
TABLE 5. CAUSES OF FAILURE IN EVALUABLE PATIENTS ACCORDING
TO TREATMENT GROUP
Cause of failure Amoxicillin-clavulanate Ceftriaxone
No. of patients 20 18
Early assessment 12 8
Died before assessment 7 4
No improvement 2 —
Clinical worsening 3 4
Acute respiratory failure 3 4
Hemodynamic failure — 2
Radiological progression 2 3
End of therapy assessment 8 9
Superinfection 2 2
Adverse effects 1 —
Change of therapy 1 1
Death 4 6
Pneumonia related 3 2
Nonrelated to pneumonia 1 4
Final assessment — 1
Superinfection — 1
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ceived combination macrolide therapy. Our data show that both
amoxicillin-clavulanate and ceftriaxone can be used against
pneumococci with penicillin MICs of 4 mg/mL. This finding
may be relevant for future recommendations, because a sub-
stantial number of pneumococci isolated from patients with
CAP have penicillin MICs between 1 and 4 mg/mL, and it is
very unusual to isolate strains with higher MICs.8,21,24,34 In our
country, penicillin resistance increased dramatically during the
1980s, but it has remained stable since then. A recent nation-
wide survey reported a resistance rate of approximately 40%
while cephalosporin resistance is increasing slightly.9,22,30 In
some European countries and the United States, with lower fig-
ures, there has been a marked increase in the prevalence of drug
resistance in the 1990s, similar to the rise recorded in Spain in
the previous decade.6,37 On the other hand, the level of resis-
tance also appears to remain stable or to increase very slowly,
and currently it is very rare to isolate pneumococcal strains with
ceftriaxone MICs higher than 2 mg/mL. The frequency of these
strains has been reported to be less than 0.5% in Spain,8 and
we did not identify any in this trial. Nevertheless, the impor-
tance of monitoring continuously the sensitivities of pneumo-
coccal isolates should be stressed because the proportion of
highly resistant strains may increase in the future.
In our study, the response to betalactam therapy did not dif-
fer between patients with pneumococcal pneumonia due to re-
sistant strains and patients with susceptible strains. Although
the more frequent isolation of highly resistant strains might have
strengthened our conclusions, our findings, involving adult pa-
tients, are in concordance with two recent retrospective studies
involving pediatric patients. These studies compared the out-
comes of patients with pneumococcal pneumonia due to either
penicillin susceptible or resistant strains and found that children
responded equally well to betalactams regadless of the peni-
cillin susceptibility of their pneumococcal isolates.5,36 In this
regard, it should be noted that the NCCLS has recently modi-
fied the criteria to define amoxicillin resistance, increasing the
MIC breakpoint from 1 to 4 mg/mL to define intermediate sus-
ceptibility, and from $2 to $8 mg/mL to define resistance.29
Nevertheless, the criteria for the extended spectrum cepha-
losporins have not yet been changed.28,29 Our view is that cur-
rent MIC breakpoints for cephalosporin resistance should also
be redefined for the treatment of nonmeningeal pneumococcal
invasive disease.
The low number of highly penicillin resistant strains (MIC $
2 mg/mL) found in the study is a reasonable reflection of the
real situation of the resistance among pneumococci causing
CAP in our area. In fact, rates of penicillin and multiple drug
resistance in this patient population were lower than those re-
ported by us in previous studies, which also included pneu-
mococcal isolates from different patient populations and
sources.21,30,31 This difference may be explained by the fact that
the present study did not include immunosuppressed patients
(AIDS and cancer patients), nosocomial pneumonias, nor spu-
tum isolates from chronic bronchitics. In addition, the distri-
bution of SGTs found in our study differed from those found
in previous studies.15,21 In fact, more than one third of the
pnemococci belonged to SGT 3, followed by SGTs 8 and 4,
which are usually penicillin susceptible. SGTs 19 and 23, which
are associated with multiresistant patterns, were observed in fre-
quencies similar to those in previous studies, while SGT 14, 9,
and 6 were less frequently found.8,21
The concern with the poor response to betalactams may lead
to frequent use of other antimicrobial agents active against re-
sistant pneumococci, such as glycopeptides or the new fluoro-
quinolones. Nowadays, there is general agreement that van-
comycin should be reserved as much as possible to avoid the
emergence of resistance among other Gram-positive organisms.
Regarding the newest fluoroquinolones, although recent clini-
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TABLE 7. TREATMENT AND OUTCOMES OF 116 PATIENTS WITH PNEUMOCOCCAL PNEUMONIA
Amoxicillin-clavulanate Ceftriaxone
Outcomes n (%) n (%)
Patient nos. 53 63
Length of therapy (mean6 SD)
intravenous 5.56 1.6 6.26 3.70
complete 11.86 9.9 11.86 5.70
Combination macrolide therapy 2 (3.8) 5 (7.9)0
Mechanical ventilation 2 (3.8) 3 (4.8)0
Time to defervescence (T# 37.0ºC) (mean6 SD) 2.66 2.2 2.86 3.60
Length of hospital stay (mean6 SD) 9.56 5.0 12.76 13.0
Adverse events 12 (22.6) 11 (17.5)
Overall mortality 5 (9.4) 7 (11.1)
early death ,48 h 3 (5.7) 2 (3.2)0
Clinical efficacya (success/total) 48/53 56/63
bacteremic 12/14 16/20
MIC of penicillin
#0.06 mg/mL 37/42 39/42
$0.12–1 mg/mL 3/3 7/8
2 mg/mL 4/4 4/6
Bacteriological efficacyb (success/total) 45/46 52/53
Baseline clinical characteristics were similar in the two groups. No differences were statisti-
cally significant. 
aAt the end of therapy. 
bTwo failures due to superinfection.
T
A
B
L
E
8.
C
L
IN
IC
A
L
C
H
A
R
A
C
T
E
R
IS
T
IC
S
A
N
D
O
U
T
C
O
M
E
S
O
F
P
A
T
IE
N
T
S
W
IT
H
P
N
E
U
M
O
C
O
C
C
A
L
P
N
E
U
M
O
N
IA
W
H
O
W
E
R
E
C
L
A
S
S
IF
IE
D
A
S
F
A
IL
U
R
E
S
A
T
A
N
Y
A
S
S
E
S
S
M
E
N
T
P
at
ie
nt
U
nd
er
ly
in
g
So
ur
ce
 o
f
M
IC
 o
f
M
IC
 o
f
M
IC
 o
f
C
au
se
 o
f
D
ay
 o
f
no
.
A
ge
/S
ex
di
se
as
e
di
ag
no
si
s
pe
ni
ci
ll
in
am
ox
ic
il
li
n
ce
ft
ri
ax
on
e
A
ss
es
sm
en
t
fa
il
ur
e
O
ut
co
m
e
de
at
h
C
au
se
 o
f 
de
at
h
A
m
ox
ic
il
li
n-
cl
av
ul
an
at
e
1
70
/M
C
O
PD
a
S
pu
tu
m
0.
03
0
0.
03
0
0.
01
5
E
ar
ly
C
li
ni
ca
l 
w
or
se
ni
ng
D
ie
d
24
E
. 
cl
oa
ca
e
no
so
co
m
ia
l
pn
eu
m
on
ia
2
35
/M
S
pl
en
ec
to
m
y
B
lo
od
0.
01
5
0.
01
5
0.
01
5
E
ar
ly
D
ea
th
D
ie
d
1
S
ep
si
s
3
80
/M
D
ia
be
te
s
S
pu
tu
m
0.
01
5
0.
01
5
0.
01
5
E
ar
ly
D
ea
th
D
ie
d
1
R
es
pi
ra
to
ry
 f
ai
lu
re
4
73
/M
L
iv
er
 c
ir
rh
os
is
B
lo
od
0.
01
5
0.
03
0
0.
01
5
E
ar
ly
D
ea
th
D
ie
d
1
R
es
pi
ra
to
ry
 f
ai
lu
re
5
68
/M
C
O
PD
S
pu
tu
m
0.
03
0
0.
01
5
0.
03
0
E
nd
 o
f 
th
er
ap
y
D
ea
th
D
ie
d
8
R
es
pi
ra
to
ry
 f
ai
lu
re
C
ef
tr
ia
xo
ne
6
30
/F
—
L
A
a (
1
) 
pl
eu
ra
l
N
A
N
A
N
A
E
ar
ly
C
li
ni
ca
l 
w
or
se
ni
ng
C
ur
ed
ef
fu
si
on
7
92
/F
C
H
Fa
B
lo
od
2
1
1
E
ar
ly
D
ea
th
D
ie
d
1
S
ep
si
s
8
67
/M
C
O
PD
T
N
A
a
0.
01
5
0.
01
5
0.
01
5
E
ar
ly
D
ea
th
D
ie
d
2
R
es
pi
ra
to
ry
 f
ai
lu
re
9
60
/M
L
iv
er
 c
ir
rh
os
is
E
m
py
em
a
1
1/
0.
5
0.
5
E
nd
 o
f 
th
er
ap
y
S
up
er
in
fe
ct
io
n
D
ie
d
23
M
R
S
A
a
se
ps
is
10
80
/M
C
R
F
a
B
lo
od
4
2
2
E
nd
 o
f 
th
er
ap
y
D
ea
th
D
ie
d
12
G
ut
 i
sc
he
m
ia
11
42
/F
L
iv
er
 c
ir
rh
os
is
B
lo
od
0.
01
5
0.
01
5
0.
01
5
E
nd
 o
f 
th
er
ap
y
D
ea
th
D
ie
d
9
M
ul
ti
or
ga
ni
c 
fa
il
ur
e
12
77
/M
—
T
N
A
, 
bl
oo
d,
0.
01
5
0.
01
5
0.
01
5
E
nd
 o
f 
th
er
ap
y
D
ea
th
D
ie
d
15
P
ul
m
on
ar
y
em
py
em
a
th
ro
m
bo
em
bo
li
sm
a C
O
P
D
, 
ch
ro
ni
c 
ob
st
ru
ct
iv
e 
pu
lm
on
ar
y 
di
se
as
e;
 C
H
F
, 
ch
ro
ni
c 
he
ar
t 
fa
il
ur
e;
 C
R
F
, 
ch
ro
ni
c 
re
na
l 
fa
il
ur
e;
 L
A
, 
la
te
x 
ag
gl
ut
in
at
io
n 
te
st
; 
T
N
A
, 
tr
an
st
ho
ra
ci
c 
ne
ed
le
 a
sp
ir
at
io
n;
 a
nd
 M
R
S
A
,
m
et
hi
ci
ll
in
-r
es
is
ta
nt
 S
. 
au
re
us
.
94
cal data support their use for the treatment of respiratory in-
fections,10 including those due to penicillin-resistant pneumo-
cocci, controlled studies focusing on patients with severe pneu-
mococcal pneumonia and bacteremia are still insufficient.17 In
a large multicenter randomized study comparing levofloxacion
with ceftriaxone/cefuroxime, File et al.10 found that lev-
ofloxacin eradicated 100% of pneumococcal isolates, although
the number of bacteremic cases was very low and no penicillin-
resistant strain was isolated in this study. Moreover, recent data
demonstrate that the prevalence of pneumococci with reduced
susceptibility to fluoroquinolones is increasing in some coun-
tries, probably as a consequence of selective pressure from the
increased use of fluoroquinolones.4 These data suggest prudent
use of these agents, reserving them for indications where they
offer a clear therapeutic advantage.4,16,20 Thus, based on the
current levels of resistance, physicians may feel comfortable
with the continuous use of appropriate betalactams in patients
with proven or suspected pneumococcal pneumonia, adding a
macrolide or a fluoroquinolone when Legionella or an atypical
pathogen cannot be reasonably ruled out. When choosing the
most appropriate betalactam agent, it should be borne in mind
that activity against penicillin-resistant pneumococci varies
greatly among different betalactams and that cephalosporins
with poor activity or an unfavorable pharmacodynamic profile
should be avoided.21,33 In this regard it should be noted that at
the dosage used of parenteral amoxicillin and ceftriaxone, the
plasma levels of both antibiotics are above 8 mg/mL during a
large percentage of the dosing interval.26,35
In conclusion, in our area where penicillin resistance is
prevalent, sequential intravenous/oral amoxicillin-clavulanate
and parenteral ceftriaxone were effective and safe for empiri-
cal treatment of hospitalized patients with acute bacterial pneu-
monia, including cases due to pneumococcal strains with peni-
cillin MICs up to 4 mg/mL. The use of appropriate betalactams
in patients with pneumococcal pneumonia is reliable at the cur-
rent level of resistance.
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